2026-03-31 12:04:36
Caribou Biosciences Receives FDA RMAT Designation for CB-011 in Multiple Myeloma
Expected Stock impact: Very Positive
On March 31, 2026, Caribou Biosciences, Inc. announced that it has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for its product candidate CB-011, an allogeneic anti-BCMA CAR-T cell therapy aimed at treating relapsed or refractory multiple myeloma (r/r MM). This designation is based on promising initial clinical data, including a reported overall response rate (ORR) of 92% and a complete response (CR) rate of 75% in a cohort of BCMA-naïve patients. The ongoing CaMMouflage phase 1 clinical trial is evaluating CB-011 in both BCMA-naïve and BCMA-exposed cohorts, with initial dose expansion and longer follow-up data expected later in 2026. The RMAT designation is intended to expedite the development and regulatory review of therapies that address unmet medical needs, providing benefits such as eligibility for priority and rolling reviews and accelerated approval if relevant criteria are met. Caribou's Chief Medical Officer, Dr. Tina Albertson, emphasized the significance of this designation, highlighting the unmet need in multiple myeloma treatment and the potential of CB-011 as a best-in-class therapy. The company looks forward to further discussions with the FDA regarding the clinical development of CB-011 and plans to report additional data this year as the trial progresses.
